{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:17:00Z","timestamp":1778588220723,"version":"3.51.4"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Boston Scientific, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alpha-blockers and 5-\u03b1- reductase inhibitors are a mainstay of lower urinary tract symptoms (LUTS)\/benign prostatic hyperplasia treatment; however, there can be associated sexual function deterioration with these agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>We compared sexual function over 5\u00a0years after continuous daily treatment with pharmaceutical agents in the NIH-Medical Therapy of Prostatic Symptoms (MTOPS) study versus a single water vapor thermal therapy (WVTT) procedure (Rezum RCT) in subjects with matched criteria for LUTS severity and prostate size.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used baseline sexual function data from cohorts of the MTOPS study (n\u00a0=\u20091157) randomized to doxazosin, finasteride, combination therapy, and placebo, and sexually active men at baseline (n\u00a0=\u200986) who received WVTT. MTOPS participants completed the Brief Male Sexual Function Inventory, while Rezum RCT participants completed the International Index of Erectile Function-15 and Male Sexual Health Questionnaire.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>Average percentage changes from baseline were developed using a linear mixed repeated measures model with fixed effects for treatment and follow-up visits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Men experienced significant worsening of sexual desire, erectile and ejaculatory function, and overall sexual satisfaction with finasteride and combination drug therapy. Men on doxazosin similarly had a significant decline in sexual desire, erectile, and ejaculatory function, but overall sexual satisfaction was preserved. WVTT patients experienced a significant increase in sexual desire and erectile function at 1-year follow-up and a significant increase in overall sexual satisfaction over 5\u00a0years. There was a significant decrease in ejaculatory function of approximately \u221210% (vs. \u221220% combination therapy) from baseline levels from 3 to 5\u00a0years of follow-up with WVTT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical implications<\/jats:title>\n                    <jats:p>WVTT is an established office-based minimally invasive surgical therapy that offers sustained improvements in LUTS with minimal to no sexual side effects when compared to pharmacologic therapies, which all demonstrated significant negative impacts on sexual function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Strength and limitations<\/jats:title>\n                    <jats:p>This study represents a novel comparison of data between two large landmark randomized controlled trials with robust clinical follow-up and little attrition. A limitation of the study is the utilization of two differing validated sexual function inventories that were utilized within each trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>WVTT may offer more favorable outcomes for sexual function compared to pharmacologic treatments, which are consistently associated with declines across multiple domains.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdag135","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:40:15Z","timestamp":1776944415000},"source":"Crossref","is-referenced-by-count":0,"title":["Sexual function outcomes of the 5-year treatment with Rezum compared to doxazosin, finasteride, and combination drug therapy for men with benign prostatic hyperplasia: cohort data from the Medical Therapy of Prostatic Symptoms Trial"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5365-0259","authenticated-orcid":false,"given":"Timothy M","family":"Han","sequence":"first","affiliation":[{"name":"Loyola University Medical Center, Department of Urology , Maywood, IL 60153, \u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Helon","sequence":"additional","affiliation":[{"name":"Loyola University, Stritch School of Medicine , Maywood, IL 60153, \u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bronwyn","family":"Long","sequence":"additional","affiliation":[{"name":"Loyola University Medical Center, Department of Urology , Maywood, IL 60153, \u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandip","family":"Cheema","sequence":"additional","affiliation":[{"name":"Loyola University Medical Center, Department of Urology , Maywood, IL 60153, \u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Loyola University, Stritch School of Medicine , Maywood, IL 60153, \u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara","family":"Joyce","sequence":"additional","affiliation":[{"name":"Loyola University Chicago , Chicago, IL 60660, \u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Feffer","sequence":"additional","affiliation":[{"name":"Loyola University Chicago , Chicago, IL 60660, \u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin T","family":"McVary","sequence":"additional","affiliation":[{"name":"Loyola University Medical Center, Department of Urology , Maywood, IL 60153, \u00a0","place":["United States"]},{"name":"Loyola University, Stritch School of Medicine , Maywood, IL 60153, \u00a0","place":["United States"]},{"name":"Center for Male Health, Loyola University Medical Center , Maywood, IL 60153 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"1","key":"2026051207561214200_ref1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s0090-4295(02)02114-3","article-title":"Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial","volume":"61","author":"Kirby","year":"2003","journal-title":"Urology"},{"issue":"25","key":"2026051207561214200_ref2","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"2026051207561214200_ref3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","article-title":"The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study","volume":"57","author":"Roehrborn","year":"2010","journal-title":"Eur Urol"},{"issue":"12","key":"2026051207561214200_ref4","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1111\/j.1743-6109.2008.01001.x","article-title":"5-alpha reductase inhibitors and erectile dysfunction: the connection","volume":"5","author":"Erdemir","year":"2008","journal-title":"J Sex Med"},{"issue":"6","key":"2026051207561214200_ref5","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/j.juro.2013.12.014","article-title":"Change in sexual function in men with lower urinary tract symptoms\/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy","volume":"191","author":"Fwu","year":"2014","journal-title":"J Urol"},{"issue":"10","key":"2026051207561214200_ref6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11934-014-0441-2","article-title":"Impact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function","volume":"15","author":"Welliver","year":"2014","journal-title":"Curr Urol Rep"},{"issue":"3","key":"2026051207561214200_ref7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/13685538.2016.1195361","article-title":"Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS\/BPH: a systematic review with meta-analysis","volume":"19","author":"Favilla","year":"2016","journal-title":"Aging Male Off J Int Soc Study Aging Male"},{"issue":"4","key":"2026051207561214200_ref8","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/bju.14057","article-title":"A prospective randomised placebo-controlled study of the impact of dutasteride\/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)","volume":"121","author":"Roehrborn","year":"2018","journal-title":"BJU Int"},{"issue":"5","key":"2026051207561214200_ref9","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.juro.2015.10.181","article-title":"Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"195","author":"McVary","year":"2016","journal-title":"J Urol"},{"issue":"6","key":"2026051207561214200_ref10","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jsxm.2016.03.372","article-title":"Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study","volume":"13","author":"McVary","year":"2016","journal-title":"J Sex Med"},{"key":"2026051207561214200_ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.urology.2017.10.023","article-title":"Three-year outcomes of the prospective, randomized controlled Rez\u016bm system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"111","author":"McVary","year":"2018","journal-title":"Urology"},{"issue":"6","key":"2026051207561214200_ref12","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.juro.2016.12.045","article-title":"Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"197","author":"Roehrborn","year":"2017","journal-title":"J Urol"},{"key":"2026051207561214200_ref13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/RRU.S143679","article-title":"Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rez\u016bm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"9","author":"Darson","year":"2017","journal-title":"Res Rep Urol"},{"issue":"12","key":"2026051207561214200_ref14","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.jsxm.2018.10.006","article-title":"Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia?","volume":"15","author":"McVary","year":"2018","journal-title":"J Sex Med"},{"key":"2026051207561214200_ref15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.urology.2025.07.016","article-title":"Five-year outcomes of water vapor therapy vs doxazosin, finasteride, and combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: cohort data from the medical therapy of prostatic symptoms trial","volume":"206","author":"Long","year":"2025","journal-title":"Urology"},{"issue":"6","key":"2026051207561214200_ref16","doi-asserted-by":"publisher","first-page":"100454","DOI":"10.1016\/j.esxm.2021.100454","article-title":"Preservation of sexual function 5 years after water vapor thermal therapy for benign prostatic hyperplasia","volume":"9","author":"McVary","year":"2021","journal-title":"Sex Med"},{"issue":"3","key":"2026051207561214200_ref17","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/JU.0000000000001778","article-title":"Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"206","author":"McVary","year":"2021","journal-title":"J Urol"},{"issue":"2","key":"2026051207561214200_ref18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.juro.2018.02.3088","article-title":"Three-year treatment outcomes of water vapor thermal therapy compared to doxazosin, finasteride and combination drug therapy in men with benign prostatic hyperplasia: cohort data from the MTOPS trial","volume":"200","author":"Gupta","year":"2018","journal-title":"J Urol"},{"issue":"12","key":"2026051207561214200_ref19","doi-asserted-by":"publisher","first-page":"e2248135","DOI":"10.1001\/jamanetworkopen.2022.48135","article-title":"Association of 5\u03b1-reductase inhibitors with dementia, depression, and suicide","volume":"5","author":"Garcia-Argibay","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/23\/6\/qdag135\/68271901\/qdag135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/23\/6\/qdag135\/68271901\/qdag135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:56:29Z","timestamp":1778586989000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/doi\/10.1093\/jsxmed\/qdag135\/8676331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdag135","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,11]]},"article-number":"qdag135"}}